Tempus AI Reports Q3 2026 Financial Results and Raises Full-Year Revenue Guidance

Tempus AI, Inc. (NASDAQ: TEM) Q3 2026 Financial Results Summary

On November 2, 2026, Tempus AI, Inc. furnished a Current Report on Form 8-K under Items 2.02 and 7.01, announcing its financial results for the third quarter ended September 30, 2026, along with updated full-year 2026 financial guidance.

---

Key Financial Highlights

• Total Revenue: Reached $411.5 million, up 23% year-over-year compared to $334.2 million in Q3 2025.
• Diagnostics Segment: Generated $303.5 million (+20% YoY), driven by a 32% volume increase in oncology testing and a 300% volume surge in Minimal Residual Disease (MRD) tests (~12,000 tests).
• Data & Applications Segment: Delivered $108.1 million (+33% YoY), led by a 29% increase in Insights revenue.
• Gross Profit: Increased 27% to $266.7 million (vs. $209.9 million in Q3 2025).
• Profitability & Cash Flow:
  • Net Loss: Narrowed significantly to $(14.9) million from $(80.0) million in Q3 2025. The net loss included $50.8 million of stock-based compensation and payroll taxes, partially offset by $42.8 million in unrealized gains on marketable securities.
  • Adjusted EBITDA: Reached $25.6 million, compared to $1.5 million in Q3 2025.
  • Cash Position: Ended the quarter with $854.4 million in cash and marketable securities.

---

Full-Year 2026 Guidance Update

• Revenue: Raised guidance to $1.600 billion to $1.605 billion.
• Adjusted EBITDA: Expected to reach approximately $65 million.

---

Strategic and Operational Developments

• Bristol Myers Squibb (BMS) Agreement: In October, announced a direct licensing collaboration to provide oncology data and models for up to $137.5 million over five years, plus an additional $55 million five-year collaboration with BMS and Pathos for Alzheimer's/dementia data, pushing year-to-date data licensing bookings past $550 million.
• Merck & Moderna Collaboration: Entered into a multi-year partnership supporting the potential commercialization of intismeran autogene, an individualized neoantigen therapy (INT).
• Personalis Acquisition (NASDAQ: PSNL): Cleared regulatory review, with the shareholder vote set for November 30, 2026.
• Regulatory Approvals: Received two FDA 510(k) clearances for Tempus ECG-PH and ECG-MR in cardiology AI applications.